# Government of the District of Columbia Office of the Chief Financial Officer



Jeffrey S. DeWitt Chief Financial Officer

## **MEMORANDUM**

то:	The Honorable Phil Mendelson Chairman, Council of the District of Columbia
FROM:	Jeffrey S. DeWitt Chief Financial Officer
DATE:	October 1, 2020
SUBJECT:	Fiscal Impact Statement – Opioid Labeling Amendment Act of 2020
<b>REFERENCE:</b>	Bill 23-535, Committee Print as provided to the Office of Revenue Analysis on September 25, 2020

### Conclusion

Funds are sufficient in the fiscal year 2021 through fiscal year 2024 budget and financial plan to implement the bill.

### Background

The bill requires<sup>1</sup> pharmacies to affix warning labels to prescription drug bottles filled with opioids. The labels must state that there is a risk of overdose and addiction when taking opioid medications. The Department of Health (DC Health) and Board of Pharmacy may specify through rulemaking where the warning label must be placed on the bottle and the color and font size of the warning label.

### **Financial Plan Impact**

Funds are sufficient in the fiscal year 2021 through fiscal year 2024 budget and financial plan to implement the bill. DC Health can establish rules with regards to opioid prescription bottle labeling without additional resources.

<sup>&</sup>lt;sup>1</sup> By amending Section 15 of the District of Columbia Certificate of Need Act of 1980, September 16, 1980 (D.C. Law 3-98; D.C. Official Code § 48-2885.14).